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1.  INTRODUCTION
As the altitude increases, the atmospheric barometric 
pressure decreases and there occurs a concomitant fall in 
the inspired partial pressure of oxygen (PiO2), even though 
the relative percentage of oxygen (FiO2) remains unaltered 
at 20.9 per cent. This lowered PiO2 creates the foundational 
stress of hypobaric hypoxia. While, this was first recognised 
in 1820 by a Russian climber Joseph Hamel who advised the 
use of supplemental oxygen on ascents of Mt. Blanc1, it was 
sometimes in the mid-nineteenth century that, Bert first showed 
the association between hypobaria triggered lowering of  PiO2 
and high altitude illness2.
This relationship is best captured by the gas-law 
equation: 
 PV = nRT 
where P = pressure, V = volume, n = number of gas molecules, 
R = universal gas constant, and T = absolute temperature. 
Since, the partial pressure of a gas,  P = Fi x B, at sea level 
given a B of 760 mmHg (PB), the partial pressure of inspired 
O2 becomes = 20.9 x 760 =159 mm Hg. This fall is most 
dramatic at 5,486 meters, which is the upper level of functional 
acclimatisation where a PB of = 395 mm Hg yields a Pi O2 of 
82 mmHg  (20.9 x 395), which is nearly half  that at sea level. 
Even at 3000 m, the height of Leh, the barometric pressure (PB) 
and inspired PO2 (PiO2) are only 70 per cent of the sea level 
values. On the summit of Mt. Everest, at 8848 m, the PiO2 is 
less than 30 per cent of its sea level value. These values signify 
the stress and challenge to the physiology at high altitude. 
2.  The ADApTATION
Taken suddenly to the top of Mt. Everest (8848 m), a person 
would lose consciousness in less than 3 min3. Taken slowly the 
same person remains alive and functional. In fact the lowest 
recorded PAO2 in a healthy individual at 8400 m on Everest 
by the Caudwell Xtreme Everest expedition was 19 mmHg 
(2.55 KPa). The stark contrast between the two scenarios is 
accounted for by the adaptive process called acclimatisation 
that tends to increase the oxygen delivery (DO2) to the tissues.
3.  The ClAssIC MODel 
The classic model holds that this increase in DO2 is 
affected by an optimisation between: (i) Pulmonary (ii) 
haematological and, (iii) cardiovascular processes. Pulmonary 
process optimisation is the first response to hypobaric hypoxia: 
hyperventilation is triggered by a combination of stimulation 
of peripheral chemoreceptor and inhibition of the central 
chemoreceptors that leads to an increased respiratory rate 
and depth. This hypoxic ventilator response (HVR) triggers 
in within a few hours of exposure to hypobaric hypoxia. This 
HVR tends to restore the falling oxygen gradient across the 
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oxygen cascade by raising the alveolar ventilation and alveolar 
PO2 (PAO2) in its wake. Since the PAO2 is a function of the alveolar 
gas equation: PAO2 = PiO2-- (PACO2)/R, so as the HVR raises 
the rate and depth of respiration, an increasing CO2 washout 
leads to a decline in PACO2 and a corresponding rise in PAO2. 
This rise in PAO2 tends to increase the partial pressure of O2 
all the way from the alveolus to the mitochondria and hence, 
improving the O2 gradients across the cascade.
Along with HVR, the second component of the pulmonary 
optimisation involves hypoxic pulmonary vasoconstriction 
(HPV) and increased pulmonary artery pressures (PAP). This 
process of HPV serves to increase the flow and re-distribute the 
blood supply towards alveoli with higher oxygen content (PAO2) 
thereby improving the ventilation perfusion (V/Q) ratio. This 
increase in alveolar ventilation generates respiratory alkalosis 
due to CO2 washout, which is metabolically compensated 
by the kidneys through increased urinary HCO3-loss. Serum 
HCO3- values of 10.8 meq/L, PACO2 of 13.3 mmHg and a pH 
of 7.53 were recorded in healthy climbers at 8400 m on Mt. 
Everest by the Caudwell Xtreme Everest Expedition. 
4.  hAeMATOlOGICAl OpTIMIsATION 
pROCess
Oxygen carriage in blood is primarily a function of 
following interactive variables: 
   CaO2 = (SaO2 x 1.34 Haemoglobin, Hb) + (0.003 x PA O2)
where 1.34 = Huffners constant (ml of O2 carried by 1 gm of 
Hb), and CaO2 is O2 carrying capacity of blood. The oxygen 
content of the blood within the frame of this CaO2 equation 
is increased by a combination of an increase in haemoglobin 
and a decrease in its affinity for O2 (i.e. a leftward shift of the 
OD curve). Hb rises during acclimatisation through a two-
step process: Acutely, as a consequence of diuresis induced 
contraction of plasma volume by 30 per cent engendering 
haemo-concentration4 and within 2-3 h of hypoxic exposure 
as a consequence of increased erythropoietin (EPO) release 
by the kidneys. However this hemo concentration induced 
increase in CaO2 also engenders a paradoxical disruption of 
microcirculatory blood flow, possibly by hyper viscosity effect 
that may decrease the tissue DO2. This paradox has been 
demonstrated by Martin et al at an altitude of 4900 m5.
While the O2 binding and carrying capacity of Hb raises, 
the affinity of O2 for Hb determined by the oxygen –dissociation 
curve (ODC), decreases thereby increasing the ease of O2 
release from Hb. 
Though the initial hyperventilation triggered respiratory 
alkalosis shifts the ODC leftwards, decreasing O2 release from 
Hb, over a period of 7 days or so an increased renal synthesis 
of 2,3-Di-phosphoglycerate (2,3- DPG) forces a right wards 
correction.
5.  CARDIOvAsCUlAR OpTIMIsATION 
pROCess
If the prime purpose of acclimatisation is to increase the 
DO2 to the tissues, then DO2 can be constructed as product of 
the oxygen carrying capacity of blood and cardiac output (Q). 
Thus DO2 = CaO2 x Q. Cardiac output (Q) is itself a product 
of: Heart rate (HR) and stroke volume (SV). Thus Q = HR x 
SV. With exposure to altitude, while Q reduces for the initial 
few weeks, it returns to sea level values after several weeks 
chiefly on the account of raised HR, despite stroke volume SV 
remaining low5.
6.  CellUlAR level OpTIMIsATION
These remain the least understood. While increased 
mitochondrial and capillary densities in the muscles were 
initially thought to play a major role in acclimatisation, 
recent work by Martin5,  et al. and Caudewell Xtreme Everest 
Expedition have shown that it was in fact altitude induced 
sarcopenia which produced a relative increase in capillary 
density. There was no true neo-vascularisation. Martin5,  et al. 
demonstrated a 30 per cent reduction in mitochondrial density 
in their muscle biopsy samples.
Hypoxia inducible Factor-I (HIF-I) is the master 
transcription factor that triggers the transcriptional activation of a 
host of hypoxia responsive genes ranging from (i) erythropoietin 
(EPO), (ii)  glycolytic enzymes such as aldolase–A (ALDA), 
Enolase-I (ENO-I), Lactic dehydrogenase–A  (LDH-A), 
phosphofructokinase–L (PKK-L) & Haemeoxygenase, (iii) 
inducible Nitirc Oxide synthase (i-NO) and (iv) vascular 
endothelial growth factor (VEGF)6. Does this classical model 
of acclimatisation explain all?  The core physiological purpose 
according to the classic model that we have considered so far 
is centred upon the optimisation of increased delivery of O2 to 
the cells through an integrated response involving increased 
ventilation, cardiac output and haemoglobin concentration 
that cumulatively serve to increase the oxygen flux across the 
oxygen cascade. 
However authors such as Grocott7,  et al.  have pointed out 
that these adaptive changes do not fully explain the observed 
inter individual differences in their levels of tolerance to 
hypobaric hypoxia. Neither the baseline Cardio-respiratory 
performance (VO2 max) nor changes in the response to chronic 
hypoxia seem to account for inter-individual difference/s in 
acclimatisation8 or performance at altitude9.  Calbet10,  et al. raise 
a troubling question: why does VO2 max still stay reduced after 
acclimatisation and normalisation of arterial oxygen content? 
In fact maximal oxygen consumption and stroke volume all 
remain reduced despite acclimatisation induced normalisation 
of blood oxygen content to sea-level values11. Cerriteli12, has 
observed that pure oxygen breathing by acclimatised individual 
with resultant oxygen content greater than at sea-level did not 
normalise the VO2 max to sea level values.
These dissonant findings signal that oxygen carriage 
and delivery is not the predominant factor accounting for 
maximal oxygen consumption at altitude. An alternative model 
suggested by work of Hochachka13,  et al., and reflected upon 
by Grocott7,  et al. re-purposes the underlying assumption away 
from the preponderance of increased oxygen flux and delivery 
towards a decrease in oxygen demand and utilisation at the 
cellular level through hibernation, stunning, pre-conditioning 
pathways or an enhanced efficiency of metabolic substrate 
use7. In fact, hypoxia tolerant species and biological systems 
rarely activate the anaerobic metabolism, they rather adapt to 
hypoxia by reducing oxygen demand (hibernation) rather than 
by increasing the oxygen supply13.
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7.  FAIlURe OF ADApTATION AND hIGh 
AlTITUDe IllNess
Acute high altitude illness (AHAI) is an aggregate of 
two syndromes: cerebral and pulmonary that can afflict un-
acclimatised climbers/trekkers ascending rapidly to high 
altitude (defined as >2,500 m) while the cerebral syndromes 
encompass- Acute mountain sickness (AMS) and high altitude 
cerebral oedema (HACO), the pulmonary syndrome typically 
refers to high altitude pulmonary oedema (HAPO).
8.  epIDeMIOlOGy AND RIsK
While the incidence of AMS among trekkers to the 
Everest base camp was around 50 per cent in those climbing 
to altitudes >4000 m in 5 days14, it was nearly 84 per cent in 
those flying directly to 3740 m15. The incidence of HAPO and 
HACO is reported to range between 1 per cent - 4.0 per cent14. 
The risk of developing AHAI is a function of 3 inter-active 
factors  (i) rate of ascent, (ii) the altitude reached (sleeping 
altitude) and (iii) individual susceptibility14. Other significant 
risk factors include a past history of high altitude illness, 
exertion and infection. Individuals with a past history of HAPE 
who ascend rapidly above 4,500 have a 60 per cent chance 
of recurrence15. It is also reported that a previous history of 
HAPE could be predictive of its recurrence16, rapid ascent 
profiles greater than 500 m a day above 3000 m create a risk for 
AHAI, as also to those who ascend rapidly to altitudes >3,500 
m in a day (e.g. Air travel)17. Maximum altitude gained too 
influences the likelihood of AHAI- AMS typically develops 
at altitudes>2,500, HAPO at > 3000 m and HACO between 
4000 m - 5000 m18. A large body of evidence points towards 
individual susceptibility as an interactive outcome between: 
genetic and environmental factors18,19. Studies on Tibetan 
and Andean populations have revealed different genetic 
phenotypes20. Increased nitrogen oxides in the acclimatisation 
of both highlanders and lowlanders has been revealed, with 
Tibetans displaying significantly higher plasma concentrations 
of nitric oxide21,22. An underlying genetic susceptibility of 
AHAI has also been associated with impaired NO synthesis 
arising from certain NO synthase polymorphisms. 
While studies on Japanese population have revealed 
correlations between polymorphisms of NO synthase gene 
with resultant lower NO synthesis and increased HAPO 
susceptibility, in a study on Caucasians, no such correlations 
could be discerned23,24.
Likewise for the ACE gene polymorphisms, while 
homozygosity for the insertion variant of ACE gene, 
associated with lower ACE levels seems to confer performance 
advantage at high altitude25,26 the association between ACE 
polymorphisms with high altitude illness is more complicated. 
While lowlander Japanese cohort showed no correlations 
between insertion/deletion ACE gene variants and the HAPE-
susceptible and HAPE-resistant cohorts27, research on high 
lander Kyrgyz cohorts have signaled an association between 
ACE gene insertion (I) allele and the risk of high latitude 
pulmonary hypertension26,27. Grocott7, et al. attempt to reconcile 
these contrasting effects of ACE & NO synthase gene alleles 
by suggesting the possibility of this variation being an outcome 
of interaction between several other gene systems28.
Genetic and epigenetic variation genes coding for hypoxia 
inducible factors (HIF), transcription factors that modify 
genetic expression in response to cellular hypoxia may also 
account for the individual variation to AHA susceptibility20.
Some work points to correlation between pulmonary 
circulation responsiveness to hypoxia and vulnerability to 
HAPO. While raised pulmonary artery pressures and pulmonary 
vascular hyper-responsiveness to hypoxia during exercise at 
sea level correlates with a higher risk of HAPO on ascent to 
altitudes23. Tibetans tend to have hypo-responsive pulmonary 
vasculature to hypoxia compared with lowlanders24.
9.  ClINICAl pReseNTATION 
AMS symptoms classically emerge between 6 h - 12 
h after arrival at high altitude, often clearing up within 24 
h - 72 h of stay at the same altitude. The core symptom of 
AMS is headache along with any of the following associated 
symptoms anorexia, nausea, vomiting, fatigue, dizziness and 
insomnia. There are no clinical signs of AMS and diagnosis is 
made exclusively by the symptom history within the context 
of recent altitude gain. Being undifferentiated, the symptom 
profile of AMS overlaps with several other common disorders 
such as dehydration, exhaustion, viral illness, hypothermia, 
hypoglycaemia, migraine and alcohol hangover.  AMS can be 
better objectivised by the Lake Louise scoring system28.
Using this system AMS is diagnosed with a score totalling 
to 3 or more in the presence of headache and recent ascent to 
high altitude by an un-acclimatised person.
HACE, which is mostly preceded by AMS, is viewed as 
an end stage of AMS. Clinically HACE is characterised by 
the emergence of: (i) altered mental state and (ii) ataxia. In a 
person with AMS, the presence of either altered mentation or 
ataxia allows for a diagnosis of HACE to be made. Absence of 
AMS, however, requires the presence of both altered mentation 
and ataxia for the diagnosis of HACE28.
In field conditions ataxia is best screened by asking the 
person to walk on heel to toe tandem along a 5 m long straight 
line. Focal neurological signs such as hemi or paraparesis are 
extremely uncommon in HACE and their presence usually 
signifies another pathophysiology like cortical vein thrombosis 
or an arterial stroke. Left untreated HACE rapidly progresses 
to coma, coning and death within 24 h.
 Table 1. AMs and hACe
system severity & score
Headache None(0)/Mild (1)/ Moderate (3)/ Severe (3) 
Gastro- intestinal None(0)/Mild (1)/ Moderate (3)/ Severe (3) 
Fatigue None(0)/Mild (1)/ Moderate (3)/ Severe (3) 
Dizziness /light 
headedness None(0)/Mild (1)/ Moderate (3)/ Severe (3)
Insomnia None(0)/not as well as usual (1)/poor sleep (2) /unable to sleep (3) 
10.  pAThOphysIOlOGy
The pathophysiology of AMS and HACE is still unclear. 
Hackett and Roach have modelled AMS & HACE around 
206
GURTOO.: DEF. LIFE SCI. J., VOL. 3, NO. 3, JULy 2018, DOI : 10.14429/dlsj.3.12921
perfusion, stress failure of alveolar capillary interfaces, or 
both. Individual susceptibility to HAPE is often associated 
with an exaggerated increase in pulmonary artery pressures as 
a response to the stress challenge of hypoxia and exercise31,32. 
The exact basis for exaggerated hypoxic pulmonary 
vasoconstriction remains undefined, although the model of 
HAPE pathophysiology proposed by Hultgren31, et al. suggests 
a primary role of (i) blunted Hypoxic ventilator response (HVR), 
(ii) hyperactive hypoxic pulmonary vasoconstrictive response, 
and (iii) Genetic vulnerability, acting in conjunction with four 
secondary variables  (i) sympathetic arousal, (ii) endothelial 
dysfunction, (iii) Cold and (iv) exercise to generate increased 
pulmonary artery pressure, which then triggers increased 
capillary pressures, endothelial stress and fluid leakage across 
the alveolar capillary interfaces. Decreased removal of sodium 
and water from the alveoli further compounds the problem of 
excessive fluid accumulation.
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Table 3. prevention and treatment of AMs and hACe
symptom sign
Decreased exercise tolerance Tachypnea
Dyspnea at rest Tachycardia
Cough Crepts or wheeze on auscultation 
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Table 4.  Diagnosis of hApe requires at least 2 symptom and 
2 sign
207
GURTOO.: DEF. LIFE SCI. J., VOL. 3, NO. 3, JULy 2018, DOI : 10.14429/dlsj.3.12921
physiology and pathophysiology: Implications and 
relevance for intensive care medicine. Crit. Care., 2007, 
11(1), 203.
 doi: 10.1186/cc5142
8. Cymerman, A.L.; Reeves, J.T.; Sutton, J.R.; Rock, P.B.; 
Groves, B.M.; Malconian, M.K.; young, P.M.; Wagner, 
P.D.& Houston, C.S. Operation Everest II: Maximal 
oxygen uptake at extreme altitude. J. Appl. Physiol., 1989, 
66(5), 2446-53.
 doi: 10.1152/jappl.1989.66.5.2446
9. Howald, H. & Hoppeler, H. Performing at extreme 
altitude: muscle cellular, sub cellular adaptations. Eur. J. 
Appl. Physiol., 2003, 90, 360-64.
 doi: 10.1007/s00421-003-0872-9
10. Calbet, J.A.; Boushel, R.; Radegran, G.; Sondergaard, H.; 
Wagner, P.D. & Saltin B. Why is VO2 max after altitude 
acclimatisation still reduced despite normalisation of 
arterial O2 content ? Am. J. Physiol., 2003, 284(2), 304-
16.
 doi: 10.1152/ajpregu.00156.2002
11. Sutton, J.R.; Reeves, J.T.; Groves, B.M.; Wagner, P.D.; 
Alexander, J.K.; Hultgren, H.N.; Cymerman, A. & 
Houston, C.S. Oxygen transport and cardiovascular 
function at extreme altitude: Lessons from operation 
everest II. Int. J. Sports Med., 1992, (S1): S13-8.
 doi: 10.1055/s-2007-1024580
12. Cerreteli, P. Limiting factors to oxygen transport on 
Mount Everest. J. Appl. Physiol., 1976, 40, 658-57.
 doi: 10.1152/jappl.1976.40.5.658
13. Hochachka, P.W.; Buck, L.T.; Doll, C.J. & Land, S.C. 
Unifying theory of hypoxia tolerance: molecular/
metabolic defense and rescue mechanisms for surviving 
oxygen lack. Proc. Natl. Acad. Sci. USA., 1996, 93(18), 
9493-8.
14. Basnyat B. & Murdoch D.R. High altitude illness. The 
Lancet, 2003, 361, 1967-74.
 doi: 10.1016/S0140-6736(03)13591-X
15. Bartsch, P.; Maggiorini, M.; Mairbaurl, H.; Vock, 
P. & Swenson, E.R. Pulmonary extravascular fluid 
accumulation in climbers. The Lancet, 2002, 360, 571-2.
 doi: 10.1016/S0140-6736(02)09723-4
16. Maggiorini, M. High altitude induced pulmonary oedema. 
Cardiovasc. Resp., 2006, 72, 41-50.
 doi: 10.1016/j.cardiores.2006.07.004
17. Luks, A.M.; McIntosh, S.E.; Grissom, C.K.; Auerbach, 
P.S.; Rodway, G.W.; Schoene, R.B.; Zafren, K. & Hackett 
P.H. Wilderness Medical Society consensus guidelines 
for the prevention and treatment of acute altitude illness. 
Wilderness Environ. Med., 2010, 21(2), 146-55.
 doi: 10.1016/j.wem.2010.03.002
18. Smedley, T. & Grocott, M.P. Acute high-altitude illness: 
Aclinically orientated review. Br. J. Pain., 2013, 7(2), 85-
94.
 doi: 10.1177/2049463713489539
19. Honigman, B.; Theis, M.K.; Koziol-McLain, J.; Roach, 
R.; yip. R.; Houston, C. & Moore, L.G. Acute mountain 
sickness in a general tourist population at moderate 
altitudes. Ann. Intern. Med., 1993, 118(8), 587-92.
 doi: 10.7326/0003-4819-118-8-199304150-00003
20. West, J.B. High altitude medicine. Am. J. Resp. Crit. Care 
Med., 2012, 186, 1229-33.
 doi: 10.1164/rccm.201207-1323CI
21. Levett, D.Z.; Fernandez, B.O.; Riley, H.L.; Martin, D.S.; 
Mitchell, K.; Leckstrom, C.A.; Ince, C.; Whipp, B.J.; 
Mythen, M.G.; Montgomery, H.E. & Grocott, M.P. The 
role of nitrogen oxides in human adaptation to hypoxia. 
Sci. Rep., 201, 1, 109.
 doi: 10.1038/srep00109
22. Erzurum, S.C.; Ghosh, S.; Janocha, A.J.; Xu, W.; Bauer, 
S.; Bryan, N.S.; Tejero, J.; Hemann, C.; Hille, R.; Stuehr, 
D.J. & Feelisch, M. Higher blood flow and circulating 
NO products offset high-altitude hypoxia among 
Tibetans. Proc. Natl. Acad. Sci. USA., 2007, 104(45), 
17593-17598.
 doi: 10.1073/pnas.0707462104
23. Dehnert, C.; Grunig, E.; Mereles, D.; Vonlennep, N. & 
Bartsch P. Identification of individuals susceptible to 
HAPO at low altitude. Eur. Respir. J., 2005, 25, 545-51.
 doi: 10.1183/09031936.05.00070404
24. Droma, y.; Hanaoka, M.; Ota, M.; Katsuyama, y.; Koizumi, 
T.; Fujimoto, K.; Kobayashi, T. & Kubo, K. Positive 
association of the endothelial nitric oxide synthase gene 
polymorphisms with high-altitude pulmonary edema. 
Circulation, 2002, 106(7), 826-30.
 doi: 10.1161/01.CIR.0000024409.30143.70
25. Hotta, J.; Hanaoka, M.; Droma, y.; Katsuyama, y.; Ota, 
M. & Kobayashi, T. Polymorphisms of renin-angiotensin 
system genes with high-altitude pulmonary edema in 
Japanese subjects. Chest, 2004, 126(3), 825-30.   
 doi: 10.1378/chest.126.3.825
26. Morrell, N.W.; Sarybaev, A.S.; Alikhan, A.; Mirrakhimov, 
M.M. & Aldashev A.A. ACE genotype and risk of high 
altitude pulmonary hypertension in Kyrghyz highlanders. 
The Lancet, 1999, 353(9155), 814.
 doi: 10.1016/S0140-6736(99)00206-8
27. Fricker, R.; Hesse, C.; Weiss, J.; Tayrouz, y.; Hoffmann, 
M.M.; Unnebrink, K.; Mansmann, U. & Haefeli, 
W.E. Endothelial venodilator response in carriers of 
genetic polymorphisms involved in NO synthesis and 
degradation. Br. J. Clin. Pharmacol., 2004, 58(2), 169-
177.
 doi: 10.1111/j.1365-2125.2004.02130.x
28. Aldashev, A.A.; Sarybaev, A.S.; Sydykov, A.S.; 
Kalmyrzaev, B.B.; Kim, E.V.; Mamanova, L.B.; Maripov, 
R.; Kojonazarov, B.K.; Mirrakhimov, M.M.; Wilkins, 
M.R. & Morrell, N.W. Characterisation of high-altitude 
pulmonary hypertension in the Kyrgyz: association with 
angiotensin-converting enzyme genotype. Am. J. Respir. 
Crit. Care Med., 2002, 166(10), 1396-1402.
 doi: 10.1164/rccm.200204-345OC
29. Cremona, G.; Asnaghi, R.; Baderna, P.; Brunetto, A.; 
Brutsaert, T.; Cavallaro, C.; Clark, T.M.; Cogo, A.; Donis, 
R.; Lanfranchi, P. & Luks A. Pulmonary extravascular 
fluid accumulation in recreational climbers: A prospective 
study. The Lancet, 2002, 359(9303), 303-9.
 doi: 10.1016/S0140-6736(02)07496-2
208
GURTOO.: DEF. LIFE SCI. J., VOL. 3, NO. 3, JULy 2018, DOI : 10.14429/dlsj.3.12921
30. Hultgren, H.N.; Honigman, B.; Theis, K. & Nichols, D. 
HAPE at a Sri resort. West J Med., 1996, 164, 222-27.
31. Hultgren, H.N.; Grover, R.F. & Hartley, L.H. Abnormal 
circulatory responses to high altitude in subjects with 
previous history of HAPO. Circulation, 1971, 44, 759-
70.
 doi: 10.1161/01.CIR.44.5.759
32. Eldridge, M.W.; Podolsky, A.; Richardson, R.S.; Johnson, 
D.H.; Knight, D.R.; Johnson, E.C.; Hopkins, S.R.; 
Michimata, H.; Grassi, B.; Feiner, J. & Kurdak, S.S. 
Pulmonary hemodynamic response to exercise in subjects 
with prior high-altitude pulmonary edema. J. Appl. 
Physiol., 1996, 81(2), 911-921.
 doi: 10.1152/jappl.1996.81.2.911
33. Hornbein, T. & Schoene R, High altitude: An exploration 
of human adaptation. Edited. CRC Press; 2001 Aug 30.
CONTRIBUTOR
Dr Anil Gurtoo is Director-Professor of Medicine at Lady 
Hardinge Medical College & associated SSK Hospital, New 
Delhi. He is an active mountaineer with a climbing experience 
that spans across 14 major Himalayan expeditions. 
